Literature DB >> 19672964

Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area.

Jin Young Kwak1, Eun-Kyung Kim, Jong-Kee Kim, Jeong-Hyun Han, Soon Won Hong, Tae Sung Park, Jong Rak Choi.   

Abstract

BACKGROUND: To evaluate the diagnostic value of dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) for the detection of BRAF(V600E) mutations in ultrasound-guided fine-needle aspiration biopsy (US-FNAB) of thyroid nodules.
METHODS: Our institutional review board approved this retrospective study, and informed consent was not required from patients. The 130 patients underwent US-FNAB to evaluate BRAF status in thyroid nodules. In FNAB washouts, DPO-based multiplex PCR, direct DNA sequencing, and PCR-restriction fragment length polymorphism (RFLP) were used to detect BRAF(V600E). The diagnostic performance of these methods was calculated. We compared cytologic results by BRAF status.
RESULTS: Diagnostic accuracy and sensitivity were highest when screening with DPO-based multiplex PCR. BRAF(V600E) positivity was a useful marker at thyroid nodules with "suspicious for papillary thyroid carcinoma" or "inadequate" cytological result.
CONCLUSIONS: DPO-based multiplex PCR may be an alternative to direct DNA sequencing because of its high sensitivity, high accuracy, and simplicity. BRAF(V600E) may be a useful additional diagnostic marker in BRAF(V600E)-prevalent areas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19672964     DOI: 10.1002/hed.21210

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  21 in total

1.  An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood.

Authors:  David J Panka; Ryan J Sullivan; James W Mier
Journal:  Melanoma Res       Date:  2010-10       Impact factor: 3.599

2.  The 5-tiered categorization system for reporting cytology is sufficient for management of patients with thyroid nodules compared to the 6-tiered Bethesda system.

Authors:  Jieun Koh; Hee Jung Moon; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

3.  The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma.

Authors:  Yun Zhang; Jiaqi Dai; Tingting Wu; Nailin Yang; Zhiqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-12       Impact factor: 4.553

4.  Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Authors:  David J Panka; Elizabeth Buchbinder; Anita Giobbie-Hurder; Aislyn P Schalck; Laleh Montaser-Kouhsari; Alireza Sepehr; Donald P Lawrence; David F McDermott; Rachel Cohen; Alexander Carlson; Jennifer A Wargo; Ryan Merritt; Virginia J Seery; F Stephen Hodi; Anasuya Gunturi; Dennie Fredrick; Michael B Atkins; A John Iafrate; Keith T Flaherty; James W Mier; Ryan J Sullivan
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

5.  Papillary thyroid cancer with Hashimoto's thyroiditis attenuates the tumour aggressiveness through the up-regulation of E-cadherin and TGF-β expression.

Authors:  Su Jin Kim; Seung-Eun Lee; Young Il Kim; Il Sung Nam-Goong; Hyo Won Jung; Eun Sook Kim
Journal:  Clin Exp Med       Date:  2022-07-24       Impact factor: 5.057

6.  The prognostic relevance of psammoma bodies and ultrasonographic intratumoral calcifications in papillary thyroid carcinoma.

Authors:  Jung-Soo Pyo; Guhyun Kang; Dong-Hoon Kim; Chanheun Park; Joo Heon Kim; Jin Hee Sohn
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

Review 7.  BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Guhyun Kang
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

8.  Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.

Authors:  Jieun Koh; Jong Rak Choi; Kyung Hwa Han; Eun-Kyung Kim; Jung Hyun Yoon; Hee Jung Moon; Jin Young Kwak
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

9.  Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis?

Authors:  Jung Hyun Yoon; Eun-Kyung Kim; Hee Jung Moon; Jin Young Kwak
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

10.  Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques.

Authors:  Nicola L Schoenewolf; Reinhard Dummer; Daniela Mihic-Probst; Holger Moch; Mathew Simcock; Adrian Ochsenbein; Silke Gillessen; Peter Schraml; Roger von Moos
Journal:  Case Rep Oncol       Date:  2012-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.